search
  • Country
    Clear
  • Thematic
    Clear
  • Type
  • Compatibility Level
  • Jurisdiction
2,012 Data sources

  • NL
  • SG
  • PK
  • EU
  • Thematic: No

  • more_vert
  • The Pathway Interaction Database is a highly-structured, curated collection of information about known biomolecular interactions and key cellular processes assembled into signaling pathways.

    more_vert
  • NeuronDB provides a dynamically searchable database of three types of neuronal properties: voltage gated conductances, neurotransmitter receptors, and neurotransmitter substances. It contains tools that provide for integration of these properties in a given type of neuron and compartment, and for comparison of properties across different types of neurons and compartments.

    more_vert
  • The Mitochondrial Disease Sequence Data Resource (MSeqDR) is a centralized genome and phenome bioinformatics resource built by the mitochondrial disease community to facilitate clinical diagnosis and research investigations of individual patient phenotypes, genomes, genes, and variants. It integrates community knowledge from expert‐curated databases with genomic and phenotype data shared by clinicians and researchers.

    more_vert
  • more_vert
  • The CESSDA Data Catalogue contains the metadata of all data in the holdings of CESSDA service providers. It is a one-stop-shop for search and discovery, enabling effective access to European research data for researchers. Details of over 40, 000 data collections are listed. These are harvested from fifteen different CESSDA Service Providers.

    more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • more_vert
  • The WHO has created a global clinical platform of patient-level anonymized clinical data. The Platform is a secure, limited-access, password-protected platform hosted on REDCap.

    more_vert
  • University of Groningen institutional repository

    more_vert
  • chevron_left
  • 1
  • 2
  • 3
  • 4
  • 5
  • chevron_right
2,012 Data sources
  • more_vert
  • The Pathway Interaction Database is a highly-structured, curated collection of information about known biomolecular interactions and key cellular processes assembled into signaling pathways.

    more_vert
  • NeuronDB provides a dynamically searchable database of three types of neuronal properties: voltage gated conductances, neurotransmitter receptors, and neurotransmitter substances. It contains tools that provide for integration of these properties in a given type of neuron and compartment, and for comparison of properties across different types of neurons and compartments.

    more_vert
  • The Mitochondrial Disease Sequence Data Resource (MSeqDR) is a centralized genome and phenome bioinformatics resource built by the mitochondrial disease community to facilitate clinical diagnosis and research investigations of individual patient phenotypes, genomes, genes, and variants. It integrates community knowledge from expert‐curated databases with genomic and phenotype data shared by clinicians and researchers.

    more_vert
  • more_vert
  • The CESSDA Data Catalogue contains the metadata of all data in the holdings of CESSDA service providers. It is a one-stop-shop for search and discovery, enabling effective access to European research data for researchers. Details of over 40, 000 data collections are listed. These are harvested from fifteen different CESSDA Service Providers.

    more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • more_vert
  • The WHO has created a global clinical platform of patient-level anonymized clinical data. The Platform is a secure, limited-access, password-protected platform hosted on REDCap.

    more_vert
  • University of Groningen institutional repository

    more_vert
  • chevron_left
  • 1
  • 2
  • 3
  • 4
  • 5
  • chevron_right